AU2002236455A1 - Synergistic ecta compositions - Google Patents

Synergistic ecta compositions

Info

Publication number
AU2002236455A1
AU2002236455A1 AU2002236455A AU3645502A AU2002236455A1 AU 2002236455 A1 AU2002236455 A1 AU 2002236455A1 AU 2002236455 A AU2002236455 A AU 2002236455A AU 3645502 A AU3645502 A AU 3645502A AU 2002236455 A1 AU2002236455 A1 AU 2002236455A1
Authority
AU
Australia
Prior art keywords
ecta
synergistic
compositions
synergistic ecta
ecta compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002236455A
Inventor
Christopher Boyer
H. Michael Shepard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celmed Oncology USA Inc
Original Assignee
Celmed Oncology USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celmed Oncology USA Inc filed Critical Celmed Oncology USA Inc
Publication of AU2002236455A1 publication Critical patent/AU2002236455A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/556Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells enzyme catalyzed therapeutic agent [ECTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
AU2002236455A 2000-11-16 2001-11-16 Synergistic ecta compositions Abandoned AU2002236455A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24972200P 2000-11-16 2000-11-16
US60/249,722 2000-11-16
PCT/US2001/043566 WO2002039952A2 (en) 2000-11-16 2001-11-16 Synergistic ecta compositions

Publications (1)

Publication Number Publication Date
AU2002236455A1 true AU2002236455A1 (en) 2002-05-27

Family

ID=22944709

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002236455A Abandoned AU2002236455A1 (en) 2000-11-16 2001-11-16 Synergistic ecta compositions

Country Status (3)

Country Link
US (1) US20020147175A1 (en)
AU (1) AU2002236455A1 (en)
WO (1) WO2002039952A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9016998A (en) * 1997-08-08 1999-03-01 Newbiotics, Inc. Methods and compositions for overcoming resistance to biologic and chemotherapy
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
CN1192102C (en) * 1998-01-23 2005-03-09 新生物生物公司 Enzyme catalyzed therapeutic agents
JP2003525866A (en) * 1999-07-22 2003-09-02 ニューバイオティックス インコーポレイテッド Methods for treating refractory tumors
US6683061B1 (en) * 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
US20030212037A1 (en) * 2000-12-21 2003-11-13 Christopher Boyer Use of bvdu for inhibiting the growth of hyperproliferative cells
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
DE102006037786A1 (en) * 2006-08-11 2008-03-20 Resprotect Gmbh Nucleosides, pharmaceuticals containing them and their use
WO2014135107A1 (en) * 2013-03-08 2014-09-12 南京圣和药业有限公司 Novel nucleoside phosphoramidate compound and use thereof
CN110731962B (en) * 2018-07-18 2022-05-20 中国医学科学院药物研究所 Application of berberine, coptisine or active metabolites thereof, and salts thereof in drugs for preventing and/or treating uric acid nephrosis
BE1026612B1 (en) * 2018-09-27 2020-07-02 Iteos Therapeutics S A USE OF AN ENT FAMILY CARRIER INHIBITOR IN THE TREATMENT OF CANCER AND COMBINATION THEREOF WITH AN ADENOSINE RECEPTOR ANTAGONIST

Also Published As

Publication number Publication date
US20020147175A1 (en) 2002-10-10
WO2002039952A2 (en) 2002-05-23
WO2002039952A3 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
AU781269C (en) Pharmaceutical compositions
AU2001234509A1 (en) Antimicrobial compositions
AU2001250420A1 (en) Pharmaceutical compositions
AU2001274307A1 (en) Pharmaceutical compositions
AU2001282617A1 (en) Compositions for external preparations
AUPQ875700A0 (en) Combination compositions
AU2001268953A1 (en) Antimicrobial compositions
AU2002214324A1 (en) Medicinal compositions
AU2001266945A1 (en) Synergistic biocidal compositions
AU2002219080A1 (en) Cleaning compositions
AU2001241098A1 (en) Composition
AU2002236455A1 (en) Synergistic ecta compositions
AU2001273919A1 (en) Pharmaceutical compositions
AU2681500A (en) Rapidly-soluble compositions
AU2002210433A1 (en) Dental compositions
AU2001270235A1 (en) Oral compositions
AUPQ634300A0 (en) Synergistic formulations
AU5085300A (en) Compositions
AU2001275201A1 (en) Acne-treating composition
AU2001259252A1 (en) Neuroprotective compositions
AU2001287852A1 (en) Composition
AU2001235764A1 (en) Compositions
AU2001290669A1 (en) Oral compositions
AU2001223721A1 (en) Dental compositions
AUPQ755300A0 (en) Immune potentiating compositions